<DOC>
	<DOCNO>NCT00162929</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose and/or maximum attainable dose vaccine consist human autologous dendritic cell transduce adenovector express rat Her-2/neu ( AdHer-2/neu ) patient metastatic breast cancer .</brief_summary>
	<brief_title>Her-2/Neu Patients With Metastatic Breast Cancer ( AdHERe )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Metastatic locally recurrent breast cancer 2 . 18 year age old 3 . Her2/neu positive ( 3+ immunohistochemistry fluorescence insitu hybridization [ FISH ] + ) 4 . One following : 1. currently receive hormonal therapy candidate , 2. consider trastuzumab , 3. cancer progress trastuzumab . 1 . Pregnant lactating woman . 2 . Prior concurrent malignancy except treat basal cell squamous cell carcinoma skin situ cancer cervix cancer treat presume cured five year prior study entry . 3 . Currently receive chemotherapy , immunotherapy , adenoviral gene therapy biological cancer therapy . [ Note : concurrent hormonal therapy ( tamoxifen , aromatase inhibitor , megace ) permit . ] 4 . Treatment trastuzumab within 4 week prior first dose vaccine therapy . 5 . Hemoglobin &lt; 80 g/L granulocyte &lt; 1.5 × 10^9/L lymphocyte &lt; 1.0 × 10^9/L platelet &lt; 100 × 10^9/L . 6 . Baseline liver enzyme ( AST ALT ) great 3 time upper limit normal great 5 time upper limit normal liver metastasis present and/or bilirubin great 50 mmol . 7 . CD4 cell &lt; 0.5 ×10^9/L 8 . Patients document brain metastasis . 9 . Patients acute illness would interfere collection CD34+ cell administration vaccination cellular therapy ( i.e . unstable angina , renal liver failure , severe chronic obstructive airway disease ) . 10 . Any patient require concurrent immunosuppressive therapy ( e.g . corticosteroid ) . 11 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . 12 . Patients life expectancy le 6 month . 13 . Geographic inaccessibility would preclude followup . Patients register trial must treat follow Juravinski Cancer Center Henderson site Hamilton Health Sciences . 14 . Failure give write informed consent . 15 . Baseline leave ventricular ejection fraction ( LVEF ) &lt; 55 % echocardiography multigated acquisition ( MUGA ) scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>locally recurrent breast cancer</keyword>
</DOC>